ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ADVM Adverum Biotechnologies Inc

9.81
-0.53 (-5.13%)
After Hours
Last Updated: 21:05:19
Delayed by 15 minutes
Share Name Share Symbol Market Type
Adverum Biotechnologies Inc NASDAQ:ADVM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.53 -5.13% 9.81 3.92 11.19 10.17 9.60 10.17 200,543 21:05:19

Adverum Biotechnologies to Host a Conference Call and Webcast to Report Third Quarter 2019 Financial Results and Provide Corp...

31/10/2019 8:01pm

GlobeNewswire Inc.


Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Adverum Biotechnologies Charts.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced today announced that it will host a conference call and audio webcast on Thursday, November 7, 2019 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to report its third quarter 2019 financial results and provide corporate updates.

Individuals can participate in the conference call by dialing 1-866-420-8347 (domestic) or 1-409-217-8241 (international) and refer to the “Adverum Biotechnologies Third Quarter 2019 Earnings Call.” The webcast will be accessible under Events and Presentations in the Investors section of the Company's website. The archived audio webcast will be available on the Adverum website following the call and will be available for 30 days.

About Adverum Biotechnologies, Inc.Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information, please visit www.adverum.com.

Investor and Media Inquiries:

Investors:Myesha LacyAdverum BiotechnologiesVice President, Investor Relations and Corporate Communicationsmlacy@adverum.com1-650-304-3892

Media:Cherilyn Cecchini, M.D.Account Supervisorccecchini@lifescipublicrelations.com 1-646-876-5196

1 Year Adverum Biotechnologies Chart

1 Year Adverum Biotechnologies Chart

1 Month Adverum Biotechnologies Chart

1 Month Adverum Biotechnologies Chart

Your Recent History

Delayed Upgrade Clock